# Measuring the molecular functional consequences of very large numbers of human genetic variants

Jay Shendure, MD, PhD Department of Genome Sciences University of Washington



The interpretation of genetic variation is a NHGRI mission-critical challenge


Variants of uncertain significance

BRCA1&2  $\rightarrow$  1M patients


Problem not going away

>1000 genome-wide associations

Small minority for which functional variant(s) known



#### **Computational Prediction?**



An Atlas of the Molecular Functional Consequences of Genetic Variation


Can we **experimentally** measure the functional consequences of **10 million** human genetic variants?

(0.1% of all possible SNVs)

# What would we gain?


- A massive training dataset for improving algorithms for predicting variant effects
- Sequence-structure-function maps for diverse elements (regulatory, protein)
- The measurements themselves, for better interpreting Variants of Uncertain Significance and fine-mapping associations

## All possible SNVs of an enhancer




Patwardhan, Hiatt et al. Nature Biotechnology (2012)

### All possible SNVs of an enhancer



## All possible codon swaps of a protein




All possible codon substitutions of an ORF in a single, multiplex reaction



Jacob Kitzman

## **BRCA1** structure-function-pathogenicity



An Atlas of the Molecular Functional Consequences of Genetic Variation

Technologies are rapidly maturing

#### **Rate-limiting factors:**

- Allelic Series Production
- Multiplex Functional Assays

Sequencing is the least of the challenges

### Which variants?


**Dense**: 2,500 x (1 Kb x 4 mutations) = 1e7

- 500 clinically relevant genes
- 2,000 *cis*-regulatory elements

Sparse: GWAS, eQTL candidates in LD blocks

- Better methods are needed
- Much more expensive per variant

### Recycle functional assays & allelic series



## Limitations of Functional Assays

"Context problem" (Botstein & Shortle, Science 1985)

- Functional assays ≠ humans
- Molecular functionality ≠ pathogenicity
- Choice of sequences & contexts informed by:



### How would this resource be used?

Rich database of experimental measurements

- Training data for better algorithms
- "Pre-computed" VUS interpretations?

Understanding biology at single-base resolution

- Protein domains, *cis-*regulatory elements
- Learn rules and extrapolate to variants in other members of a functional class

## What will success depend on?

- (\$15M x 5 yrs) / 10M variants = <u>\$30K per 1 Kbp</u>
- Doped oligonucleotide synthesis relatively cheap
- Scaling construction of allelic series
- Multiplex, scalable, recyclable functional assays

- NHGRI: funding, coordination, scaling
- Phase I (100K)  $\rightarrow$  Phase II (1M)  $\rightarrow$  Phase III (10M)
- Technology & assay development throughout